GE Marquette Medical Systems and CardioDynamics Announce JOINT Technology Development Agreement.

Business Editors/Health & Medical Writers

MILWAUKEE and SAN DIEGO--(BW HealthWire)--July 11, 2000

GE Marquette Medical Systems (NYSE:GE) and CardioDynamics International Corp. (Nasdaq:CDIC) today announced that the companies have signed an agreement to jointly develop and integrate CardioDynamics' proprietary BioZ(R) Impedance Cardiography (ICG) technology into GE Marquette's Solar(R) patient monitoring systems.

The agreement expands the present business relationship between the companies, which provides GE Marquette with exclusive rights to market and sell BioZ products to hospitals in the United States and select international markets.

"Clinicians are seeking technologies that will help them effectively and non-invasively measure a patient's cardiac function, which is especially important for critically ill patients," said Adam Miller, vice president and general manager, Cardiology Systems for GE Marquette. "Our technology agreement with CardioDynamics is further evidence of our commitment to provide healthcare professionals with medical systems that optimize the assessment and treatment of patients with cardiac conditions."

This collaboration between GE Marquette and CardioDynamics will allow the companies to combine research and development resources to accelerate development of ICG technologies. The BioZ ICG module is expected to be available in Solar patient monitoring systems in the first half of 2001.

"We are very excited about this technology development partnership with GE Marquette and believe it is the next important step in our strategy to compete aggressively in an estimated $2 billion noninvasive hemodynamic monitoring hospital market," stated Michael K. Perry, chief executive officer of CardioDynamics. "A key element of our business strategy is to establish long-term partnerships with leading companies whose interests are complimentary to ours. Integrating our proprietary ICG technology with GE Marquette's world-class Solar monitoring systems will help enable us to provide the medical community with innovative solutions for cardiac care."

GE Marquette Medical Systems is a global leader in medical information and technology. GE Marquette's offering, including cardiology, patient monitoring and healthcare information management systems, enhances patient care in medical facilities around the world. GE Marquette is a GE Medical Systems Co. with global headquarters in Milwaukee.

GE Medical Systems is a $7 billion global leader in medical technology and services, employing nearly 20,000 people worldwide. Additional information about GE Marquette and its products can be found on the company's Web site at www.gemedicalsystems.com.

CardioDynamics, with headquarters in San Diego, is a medical technology and information solutions company committed to fundamentally changing the way hemodynamic monitoring is performed in healthcare. The company's primary products, BioZ(R) System and BioZ.com(R), utilize proprietary Impedance Cardiography (ICG) to noninvasively provide medical professionals with hemodynamic data not previously available in the physician's office and many hospital settings.

Just as Electrocardiography (ECG) noninvasively measures the heart's electrical characteristics, ICG makes it possible to noninvasively measure the heart's mechanical (blood flow) characteristics. For additional information, please refer to the company's Web site at www.cdic.com.

Forward-Looking (Safe Harbor) Statement:

Note: Except for the historical and factual information contained herein, this press release contains forward-looking statements, the accuracy of which are necessarily subject to uncertainties and risks, which include sole dependence on the BioZ product line, competition from Baxter Healthcare Corp. (manufacturer of the Swan-Ganz(R) device), further capital requirements, and various uncertainties characteristic of companies just emerging from the development stage; as well as other risks detailed in the company's filings with the SEC, including its 1999 Form 10-KSB. The company does not undertake to update the disclosures contained in this press release.